Luteolin is a natural compound known for its anticancer effects on various human cancers by regulating signal transduction cascades. However, the effects of luteolin on human placental choriocarcinoma are not known. Results of the present study revealed that luteolin decreased viability of JAR and JEG-3 cells, which are valuable placental models, in a dose-dependent manner, and it induced apoptosis and loss of mitochondrial membrane potential in JAR and JEG-3 cells. The results also suggested that the PI3K/AKT pathway was inhibited by luteolin treatment of JAR and JEG-3 cells in a dose-and time-dependent manner. Next, we established effects of luteolin in the presence of pharmacological inhibitors of PI3K/AKT, ERK1/2 MAPK, and mTOR on proliferation of JAR and JEG-3 cells. In addition, these inhibitors were used to verify phosphorylation of AKT, GSK3be-ta, and ERK1/2 and to confirm mechanisms regulated by luteolin in JAR and JEG-3 cells. We also determined levels of SREBP1 and SREBP2 expression to investigate regulatory functions of luteolin in lipid metabolism in JAR and JEG-3 cells. Expression levels of both SREBP1 and SREBP2 mRNAs were significantly reduced, but only SREBP1 protein was influenced by luteolin. We compared viability of JAR and JEG-3 cells in response to luteolin alone or in combination with other chemotherapeutic drugs (etoposide, cisplatin, and paclitaxel) and found that luteolin has synergistic effects with the conventional chemotherapeutic drugs as an anticancer agent. Collectively, these results showed that luteolin plays an important role in the treatment of human choriocarcinoma cells by inhibiting the PI3K/AKT/mTOR/SREBP cascade and expression of lipogenic genes.
INTRODUCTION
Choriocarcinoma is a malignant trophoblastic cancer which has the potential risk of distant metastasis to lung, liver, brain, and kidney [1] . Although most choriocarcinoma patients have a survival rate of more than 80%, even with high-risk disease, after treatment with the first-line regimen etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine (EMA-CO), some patients do not respond or they relapse and show low survival rates due to chemoresistance [2] . Therefore, development of new and effective therapeutic agents is necessary.
Flavonoids are contained in various plants and have many therapeutic functions represented by anti-inflammatory and antioxidant effects through modulation of intracellular mechanisms at biochemical or gene expression levels [3] . Luteolin (3 0 ,4 0 ,5,7-tetrahydroxyflavone) is a member of the flavonoid family of molecules in various fruits and vegetables such as celery, parsley, and broccoli, and it has antiproliferative effects on various types of tumors including gastric, prostate, and lung cancers [4] [5] [6] . Luteolin targets a variety of molecules in cancer cells with antiproliferative activity. Phosphatidylinositol 3-kinase (PI3K)/AKT and extracellular signal-regulated kinase 1/ 2 (ERK1/2) are signaling molecules involved in most types of cancer cell growth and survival, and major molecular targets of luteolin used in cancer therapy are included in those signaling pathways [7] [8] [9] .
AKT regulates activity of multiple downstream molecules including p70S6 kinase (P70S6K), glycogen synthase kinase 3 beta (GSK3b), and mammalian target or rapamycin (mTOR) by binding and phosphorylating these proteins, and they modulate intracellular metabolism in an optimized condition for survival of cancer cells [10, 11] . Among these molecules, mTOR plays a critical role in lipogenic metabolism by regulating activity of sterol regulatory element binding protein (SREBP) [12] . Alterations in lipid metabolism are now considered an important feature of cancer cells because lipids store energy, are components of cellular membranes, and act as signaling molecules [13] . SREBP, basic helix-loop-helix leucine (bHLH) zipper transcription factor, is a master regulator of lipid metabolism involved in fatty acid and cholesterol synthesis [14] . Therefore, SREBP is a novel molecular target for treatment of cancers. Consistent with these results, fatostatin, a nonsterol diarylthiazole derivative which acts as an SREBP inhibitor, is known for antitumor activity [15] . Although some plant-derived natural products such as silibinin and cacalol have antitumor activity by modulating the AKT-SREBP pathway in prostate and breast cancer, the role of SREBP in human choriocarcinoma cells is not known [16, 17] . Moreover, studies of luteolin-mediated anticancer effects on choriocarcinoma cells are very limited.
In the present study, we investigated the effects of luteolin on the human choriocarcinoma cells JAR and JEG-3. The aims of this study were 1) to determine the functional roles of luteolin to effect changes in viability and apoptosis of JAR and JEG-3 cells; 2) to estimate the molecular mechanism mediated by luteolin, especially on the PI3K/AKT/mTOR signaling pathways in JAR and JEG-3 cells; 3) to confirm expression of lipogenic genes regulated by SREBP in JAR and JEG-3 cells; and 4) to compare the effects of therapeutic activities of luteolin alone with those of a combination of conventional anticancer agents on progression of choriocarcinoma cells. Our results indicated that luteolin is a potential therapeutic chemical for treating choriocarcinomas by inhibiting the PI3K/AKT/ mTOR/SREBP cell signaling pathway.
MATERIALS AND METHODS

Chemicals
Luteolin (catalog no. L9283), cisplatin (catalog no. P4394), etoposide (catalog no. E1383) and paclitaxel (catalog no. T7191) were purchased from Sigma-Aldrich, Inc (St. Louis, MO). U0126 and rapamycin were from Enzo Life Science (Farmingdale, NY), and LY294002 was from Cell Signaling ), and total AKT, ERK1/2, GSK3b, mTOR, P70S6K, and P90RSK were purchased from Cell Signaling Technology.
Cell Culture
HTR8/SVneo, JAR, and JEG-3 cells were purchased from American Type Culture Collection (Manassas, VA). HTR8/SVneo and JAR cells were maintained in RPMI-1640 medium with 2.05 mM L-glutamine (catalog no. SH30027.01; HyClone, Carlsbad, CA). JEG-3 cells were maintained in minimum essential medium (catalog no. 11095-080; Gibco) with 10% fetal bovine serum at 378C in an incubator with an atmosphere of 5% CO 2 . For experiments, monolayer cultures of HTR8/SVneo, JAR, and JEG-3 cells were grown in culture medium to 70% confluence in 100-mm tissue culture dishes. Cells were serum starved for 24 h and then treated with luteolin.
Proliferation Assay
Proliferation assays were conducted using ELISA cell proliferation bromodeoxyuridine (BrdU) kit (catalog no. 11647229001; Roche, Indianapolis, IN) according to the manufacturer's recommendations. Briefly, cells were seeded in a 96-well plate and then incubated for 24 h in serum-free medium. Cells were then treated with luteolin and various treatments in a final volume of 100 ll/well. To compensate for total volume of vehicle in each well, we added vehicle up to the highest treated dose for each assay. After 48 h of incubation, 10 lM BrdU was added to the cell culture, and the cells were incubated for an additional 2 h at 378C. After we labeled cells with BrdU, the fixed cells were incubated with anti-BrdU-peroxidase (POD) working solution for 90 min. The anti-BrdU-POD binds to BrdU incorporated in newly synthesized cellular DNA, and these immune complexes were detected by the reaction to tetramethylbenzidine (TMB) substrate. The absorbance values of the reaction product were quantified by measuring the absorbance at 370 nm and 492 nm, using an ELISA reader. 
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Immunofluorescence Microscopy
The effects of luteolin on the expression of proliferating cell nuclear antigen (PCNA), sterol regulatory element binding proteins 1 (SREBP1) and SREBP2 were determined by immunofluorescence microscopy. Cells were probed with mouse antihuman monoclonal PCNA (catalog no. sc-56; Santa Cruz Biotechnology, Dallas, TX) at a final dilution of 1:100 (2 lg/ml), polyclonal antihuman SREBP1 (catalog no. ab28481; Abcam, Cambridge, UK), at a final dilution of 1:200 (5 lg/ml), and polyclonal antihuman SREBP2 (catalog no. ab155017; Abcam) at a final dilution of 1:200 (1.85 lg/ml). Cells were then incubated with goat antimouse immunoglobulin G (IgG) Alexa 488 (catalog no. A-11001; Invitrogen, Carlsbad, CA) for PCNA, or goat antirabbit IgG Alexa 488 (catalog no. A-11008, Invitrogen) for SREBP1 and SREBP2 at a 1:200 dilution for 1 h at room temperature. Cells were then washed using 0.1% bovine serum albumin in phosphate-buffered saline (PBS) and overlaid with 4 0 ,6-diamidino-2-phenylindole (DAPI; catalog no. D8417; Sigma-Aldrich). For each primary antibody, images were examined using a LSM710 (Carl Zeiss) confocal microscope fitted with a digital microscope Axio-Cam camera with Zen2009 software.
TUNEL Assay
JAR and JEG-3 cells (3 3 10 4 cells per 300 ll) were seeded on confocal dishes (catalog no. 100350; SPL Life Science, Republic of Korea) and then incubated for 24 h in serum-free medium. Cells were then treated with luteolin at a final concentration of 20 lM for 48 h at 378C in a CO 2 incubator. After incubation, the cells were air dried and fixed with 4% paraformaldehyde in PBS for 1 h at room temperature. The cells were rinsed with PBS briefly and permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate for 2 min on ice. Then, the cells were subjected to TUNEL staining, using an in situ cell death detection kit, TMR red (Roche) for 1 h at 378C in the dark. Cells then were washed with PBS and overlaid with DAPI. Fluorescence was detected using a LSM710 confocal microscope.
Determination of Apoptosis by Annexin V and Propidium Iodide Staining
Apoptosis of JAR and JEG-3 cells induced by luteolin was analyzed using a Fluorescein isothiocyanate (FITC) annexin V apoptosis detection kit I (BD Biosciences, Franklin Lakes, NJ). The cells (4 3 10 5 cells) were seeded on 6-well plates and incubated for 24 h in serum-free medium when cells were at 70%-80% confluence. Then, cells were treated with luteolin in a dosedependent manner for 48 h at 378C in a CO 2 incubator. Supernatants were removed from culture dishes and adherent cells detached with trypsin-EDTA. The cells were collected by centrifugation, washed twice with PBS, and resuspended in 13 binding buffer. Then, 100 ll of the cell suspension was transferred to a 1.5-ml tube and incubated with 5 ll of FITC annexin V and 5 ll of propidium iodide (PI) for 15 min at room temperature in the dark. Then, 400 ll of 13 binding buffer was added to the 1.5-ml tube. Stained cells were transferred to a 5-ml round-bottom tube for cytometric analysis. Fluorescence intensity was analyzed using a flow cytometer (BD Biosciences).
JC-1 Mitochondrial Membrane Potential Assay
JC-1 mitochondrial membrane potential (MMP) changes were analyzed using a mitochondria staining kit (catalog no. CS0390; Sigma-Aldrich). The cells (5 3 10 5 cells) were seeded on 6-well plates and incubated for 24 h in serum-free medium to 70% confluence. Then, cells were treated with luteolin in a dose-dependent manner for 48 h at 378C in a CO 2 incubator. Supernatants were removed from culture dishes and adherent cells detached with trypsin-EDTA. The cells were collected by centrifugation, resuspended in staining solution including 2003 JC-1 at 13 staining buffer and incubated at 378C in a CO 2 incubator for 20 min. The stained cells were collected by centrifugation and washed once with 13 JC-1 staining buffer. After being washed, the cell suspension was centrifuged once more, and the cells were resuspended in 1 ml of staining buffer. Fluorescence intensity was analyzed by using a FACSCalibur (BD Biosciences).
Protein Extraction
JAR and JEG-3 cells were cultured in 100-mm dishes for 24 h in serum-free medium. Both the JAR and the JEG-3 cells were treated with luteolin (0-20 lM) for 30 min in a dose-dependent manner and incubated with 20 lM luteolin for 0-120 min in a time-dependent manner. Thereafter, the medium was removed, and the cells were rinsed twice with ice-cold PBS containing calcium and magnesium. The cells were then lysed for 30 min at 48C in 150 ll of IP lysis buffer consisting of 1% Triton X-100, 0.5% Nonidet P-40, 150 mM NaCl, 100 mM Tris-HCl (pH 7.6), 1 mM EDTA, 1 mM ethylene glycol tetra-acetic acid, 0.2 mM Na 3 VO 4 , and complete EDTA-free protease inhibitor cocktail. Cell lysates were centrifuged (21 000 3 g for 15 min at 48C). Finally, each supernatant was transferred to a clean 1.5-ml tube and stored at À808C until analyzed.
FIG. 3.
Effects of luteolin in a dose-dependent manner on activation of AKT, P70S6K, GSK3b, ERK1/2, and P90RSK in JAR and JEG-3 cells. Phosphorylated AKT (A), P70S6K (B), GSK3b (C), ERK1/2 (D), and P90RSK (E) were estimated in response to luteolin in a dose-dependent manner (0, 5, 10, and 20 lM). Immunoblots were examined to calculate the normalized values by estimation of expressed levels from phosphorylated proteins relative to total protein. *Significant differences compared to untreated controls (***P , 0.001; **P , 0.01; *P , 0.05).
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Western Blot Analysis
Concentrations of proteins in whole-cell extracts were determined using the Bradford protein assay (Bio-Rad, Hercules, CA) with bovine serum albumin as the standard. Proteins were denatured, separated using SDS-PAGE, and transferred to nitrocellulose membranes. Blots were developed using enhanced chemiluminescence detection (SuperSignal West Pico; Pierce, Rockford, IL) and quantified by measuring the intensity of light emitted from correctly sized bands under ultraviolet light, using ChemiDoc EQ system and Quantity One software (Bio-Rad). Immunoreactive proteins were detected using goat antirabbit polyclonal antibodies against phosphor-proteins and total proteins at a 1:1000 dilution and 10% SDS-PAGE. As a loading control, total proteins were used to normalize results from detection of proteins by Western blotting. All antibodies were from Cell Signaling Technology. Multiple exposures of each Western blot were performed to ensure linearity of chemiluminescent signals. These experiments were performed in triplicate.
Quantitative RT-PCR Analysis
For cellular RNA isolation, JAR and JEG-3 cells were seeded on 6-well plates and incubated for 24 h in serum-free medium. Then, cells were treated with luteolin at a final concentration of 20 lM for 48 h at 378C in a CO 2 incubator. Total cellular RNA was isolated using Trizol reagent (Invitrogen) according to manufacturer's recommendations. Complementary DNA was synthesized using total RNA (1 lg) and AccuPower RT PreMix (Bioneer, Daejeon, Korea). Gene expression levels were measured using SYBR Green (Sigma-Aldrich) and a StepOnePlus Real-Time PCR system (Applied Biosystems, Foster City, CA). Primer sets are listed in Table 1 . Using the standard curve method, we determined the level of expression of target genes using the standard curves and cycle threshold (C T ) values, and normalized them based on GAPDH expression. The PCR conditions were 958C for 3 min, followed by 40 cycles at 958C for 30 sec, 608C for 30 sec, and 728C for 30 sec, using a melting curve program (increasing the temperature from 558C to 958C at a rate of 0.58C per 10 sec) and continuous fluorescence measurement. ROX   FIG. 4 . Time-dependent effects of luteolin on phosphorylation of AKT, GSK3b, and ERK1/2 proteins in JAR and JEG-3 cells. Phosphorylated AKT (A), GSK3b (B), and ERK1/2 (C) were estimated at 0, 5, 15, 30, 60, and 120 min after incubation with luteolin. Immunoblots were examined to calculate the normalized values by estimation of expressed levels from phosphorylated proteins relative to those of total protein. *Significant differences compared to untreated controls cells (***P , 0.001; **P , 0.01; *P , 0.05).
LUTEOLIN BLOCKS PROLIFERATION OF CHORIOCARCINOMA dye (Invitrogen) was used as a negative control for the fluorescence measurements. Sequence-specific products were identified by generating a melting curve in which the C T value represented the cycle number at which a fluorescent signal was statistically greater than background, and relative gene expression was quantified using the 2 -DDCT method.
Statistical Analysis
Data for proliferation and migration assays were subjected to analysis of variance (ANOVA) according to the general linear model (PROC-GLM function) of SAS software (Cary, NC) to determine whether there were significant effects on proliferation or migration of choriocarcinoma cells in response to treatments. Differences with a P value of ,0.05 were considered statistically significant. Data are mean 6 SEM unless otherwise stated.
RESULTS
Luteolin Reduces Human Choriocarcinoma Cells' Viability
We investigated dose-dependent (0, 5, 10, 20, 50, and 100 lM) effects of luteolin on viability of trophoblast cells (HTR8/SVneo) and choriocarcinoma cells (JAR and JEG-3). Cell viability was expressed as a percentage of untreated control cells (Fig. 1A ). There were no effects of luteolin on viability of HTR8/SVneo cells. However, concentrations of luteolin at 5 lM and above reduced survival of JAR and JEG-3 cells to less than 50% (P , 0.001). We then localized PCNA, an essential DNA replication accessory protein, in luteolin-treated and -untreated choriocarcinoma cells by immunofluorescence microscopy. As shown in Figure 1B , there was abundant expression of PCNA nuclei of control choriocarcinoma cells, but PCNA was barely detectable in luteolin-treated choriocarcinoma cells. These findings indicated that luteolin strongly suppressed proliferation of human choriocarcinoma cells.
Luteolin Induces Apoptosis in Choriocarcinoma Cells
To determine apoptotic effects of luteolin on choriocarcinoma cells, we performed a TUNEL assay to detect DNA fragmentation as evidence by labeling of DNA with tetramethyl-rhodamine-dUTP ( Fig. 2A) . Although apoptosis was readily detected in luteolin-treated cells, there was little evidence of apoptosis in nuclei of control JAR and JEG-3 cells. Also, the level of apoptosis induced by luteolin was confirmed using flow cytometry following staining with FITC-coupled Annexin V and propidium iodide (PI) (Fig. 2, B and C) . In JAR cells, the relative degree of cell death increased 488% in response to 20 lM luteolin compared to that of control cells. Also, the number of apoptotic cells increased 703% in JEG-3 cells treated with 20 lM luteolin compared to that of untreated JEG-3 cells. Furthermore, loss of MMP, analyzed using JC-1 staining to estimate depolarization of mitochondria (Fig. 2, D and E), increased in choriocarcinoma cells treated with luteolin in a dose-dependent manner. Depolarization of MMP increased approximately 146.6% and 677% in JAR and JEG-3 cells, respectively, when treated with 20 lM luteolin compared to untreated control cells Collectively, results from multiple analyses revealed that luteolin induced apoptosis in both of the human choriocarcinoma cell lines.
Luteolin Attenuates PI3K/AKT Signaling Pathways and Upregulates ERK1/2 MAPK in Choriocarcinoma Cells
We performed Western blot analyses to determine whether PI3K/AKT or ERK1/2 signaling pathways were involved in responses of JAR and JEG-3 cells to luteolin. Luteolin reduced phosphorylation of AKT and P70S6K in a dose-dependent manner in both JAR and JEG-3 cells (Fig. 3, A and B) . Luteolin also up-regulated phosphorylation of GSK3b at 20 lM compared to untreated JAR cells but inhibited phosphorylation of GSK3b in a dose-dependent manner in JEG-3 cells (Fig. 3C) . Phosphorylated ERK1/2 (p-ERK1/2) increased in response to 5 lM and 20 lM luteolin in both the JAR and JEG-3 cells (Fig. 3D ). Luteolin inhibited (P , 0.01) phosphorylation of P90RSK in JAR cells but increased (P , 0.01) activated P90RSK in JEG-3 cells (Fig. 3E) . Consistent with the dose-dependent effects of luteolin, phosphorylated AKT (p-AKT) decreased in response to 20 lM luteolin in a timedependent manner for JAR and JEG-3 cells (Fig. 4A) . Also, luteolin increased (P , 0.001) phosphorylation of GSK3b in a time-dependent manner in JAR cells, but did not affect activation of GSK3b in JEG-3 cells (Fig. 4B) . The abundance of p-ERK1/2 increased (P , 0.001) in a time-dependent manner after luteolin treatment of both JAR and JEG-3 cells. These results indicated differential effects of luteolin to decrease AKT and increase ERK1/2, whereas luteolin also increased GSK3b in JAR but not JEG-3 cells. Cell numbers were estimated in a cell proliferation assay, and data are percentages relative to untreated control JAR and JEG-3 cells (100%). *Significant differences compared to untreated controls (***P , 0.001; **P , 0.01; *P , 0.05).
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FIG. 6. Effects of pharmacological inhibitors alone and in combination with luteolin on activation of PI3K and ERK1/2 MAPK signaling pathways in JAR and JEG-3 cells. Phosphorylated AKT (A), GSK3b (B), and ERK1/2 (C) were analyzed in response to pretreatment with inhibitors (LY294002, U0126, and rapamycin) for 1 h before treatment with luteolin (20 lM) for 30 additional minutes. Immunoblots were examined to calculate the normalized values by estimation of expressed levels from phosphorylated proteins relative to total protein. *Significant differences compared to untreated controls (***P , 0.001; **P , 0.01; *P , 0.05).
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Inhibition of Proliferation of Choriocarcinoma Cells by Inhibiting PI3K/AKT and ERK1/2 Signaling Pathways with Luteolin
To determine whether there was a decrease in cell viability in response to luteolin related to the PI3K, ERK1/2, and mTOR cell signaling pathways, we performed proliferation assays with JAR and JEG-3 cells treated with luteolin alone and with LY294002 (a PI3K inhibitor; 20 lM), U0126 (an ERK1/2 inhibitor; 10 lM), and rapamycin (an mTOR inhibitor; 10 lM) (Fig. 5) . Treatment with luteolin alone decreased proliferation of JAR (P , 0.01) and JEG-3 (P , 0.001) cells. The combination of luteolin and LY294002, U0126 or rapamycin decreased proliferation of JAR cells to a greater extent than for luteolin alone and each pharmacological inhibitor alone (Fig.  5A ). In the case of JEG-3 cells, however, only treatments that included luteolin and U0126 decreased cell proliferation to a greater extent than luteolin alone or U0126 alone. These results indicate that both PI3K/AKT and ERK1/2 signaling pathways are involved in antiproliferative effects of luteolin, but imply that cellular mechanisms differ between JAR and JEG-3 cells.
Inhibition of PI3K/AKT and ERK1/2 Signaling Pathways in Choriocarcinoma Cells Affects Phosphorylation of Signaling Molecules Mediated by Luteolin
To further elucidate the antiproliferative mechanism mediated by luteolin in choriocarcinoma cells, we estimated phosphorylation of AKT, GSK3b, and ERK1/2 in choriocarcinoma cells pretreated with LY294002, U0126, and rapamycin or a combination of these agents before incubation with luteolin. As shown in Figure 6A , luteolin-induced AKT inactivation was not reduced further by inhibition ERK1/2 or mTOR in JAR cells (Fig. 6A) . Although phosphorylation of GSK3b was not influenced by any of the inhibitors in JAR cells, all inhibitors acted in concert with luteolin to further decrease (P , 0.01) phosphorylation of GSK3b (Fig. 6B) . In both JAR and JEG-3 cells, expression of p-ERK1/2 increased (P , 0.001) in response to the PI3K inhibitor; however, the combination of luteolin and U0126, and luteolin with three inhibitors decreased (P , 0.01) phosphorylation of ERK1/2 in both JAR and JEG-3 cells (Fig. 6C) . These results indicate that the effects of luteolin-mediated effects on JAR and JEG-3 cells involve reduction of phosphorylation of PI3K/AKT cell signaling pathway and an increase in the ERK1/2 cell signaling pathway.
Luteolin Inhibits Activation of mTOR and SREBP-Mediated Transcriptional Activity
To determine whether PI3K/AKT/mTOR-mediated lipogenic activity is down-regulated by luteolin in choriocarcinoma cells, we first estimated changes in expression of SREBP mRNAs and proteins. As shown in Figure 7A , luteolin significantly decreased expression of SREBP1, SREBP2, and SREBP cleavage-activating protein (SCAP) mRNAs in JAR and JEG-3 cells. Also, phosphorylation of mTOR was decreased (P , 0.001) by luteolin in a dose-dependent manner in JAR and JEG-3 cells (Fig. 7B) . Furthermore, we detected dose-dependent decreases in SREBP1 protein in JAR and JEG-3 cells in response to luteolin (Fig. 7C) . However, expression of SREBP2 was not influenced by luteolin treatment in either JAR and JEG-3 cells (Fig. 7D) . Immunofluorescent analyses revealed that SREBP1 was abundant in nuclei of untreated choriocarcinoma cells, but weakly detectable in cytoplasm of JAR and JEG-3 cells treated with luteolin (Fig. 8A) . The 
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SREBP2 protein was localized exclusively to the cytoplasm and its abundance was not affected by JAR or JEG-3 cells treated with luteolin (Fig. 8B) . Next, we determined transcriptional expression of SREBP-mediated target genes influenced by luteolin, including fatty acid synthase (FASN), acetyl-CoA carboxylase alpha (ACACA), peroxisome proliferator-activated receptor gamma (PPARc), diazepam binding inhibitor (DBI), stearoyl-CoA desaturase (SCD), 3-hydroxy-3-methylglutarylCoA reductase (HMGCR), 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1), farnesyl-diphosphate farnesyltransferase 1 (FDFT1), mevalonate kinase (MVK), and squalene epoxidase (SQLE). Expression of most of those lipogenic genes was significantly decreased by luteolin, the exception being DBI (diazepam binding inhibitor) that is an acyl-CoA-binding protein (Fig. 9) . These results suggest that luteolin has antilipogenic functions by down-regulating mTOR and SREBP1 functions.
Synergistic Effects of Luteolin with Conventional Chemotherapeutic Drugs to Inhibit Proliferation of Choriocarcinoma Cells
To compare cytotoxic anticancer effects of luteolin, we performed cell proliferation assays with JAR and JEG-3 cells treated with luteolin (5 lM), etoposide (20 lM; a topoisomerase inhibitor drug), cisplatin (20 lM; a platinum-based drug), or paclitaxel (5 lM; a taxene-based drug) and their combinations (Fig. 10) . For JAR cells, luteolin, etoposide, cisplatin, and paclitaxel each decreased proliferation of JAR cells by 60.3% (P , 0.01), 70.4% (P , 0.01), 87% (P , 0.001) and 86.7% (P , 0.01), respectively (Fig. 10A) . The combination of luteolin and etoposide decreased proliferation of JAR cells to a greater extent than etoposide or luteolin alone (P , 0.05). For JEG-3 cells, luteolin decreased proliferation 57.1% (P , 0.01) compared to untreated control JEG-3 cells (Fig. 10B) . Unlike effects on viability of JAR cells, the anticancer effects of etoposide and paclitaxel on JEG-3 cells were relatively weak, with decreases in proliferation of 35.7% (P , 0.05) and 29.5% (P , 0.05). In addition, the JEG-3 cells LUTEOLIN BLOCKS PROLIFERATION OF CHORIOCARCINOMA exhibited resistance to cisplatin, which had only a slight effect on proliferation. However, the combination of luteolin with etoposide, cisplatin or paclitaxel decreased proliferation of JEG-3 cells to a greater extent than luteolin alone or that for each chemotherapeutic agent alone (P , 0.05). These results suggest that luteolin itself possesses anticancer properties and it acts to enhance anticancer properties of standard chemotherapeutics on choriocarcinoma cells by preventing chemoresistance.
DISCUSSION
Results of the present study verified the functional antitumor role of luteolin on human choriocarcinoma JAR and JEG-3 cells. We demonstrated that luteolin reduced proliferation and induced cell death in JAR and JEG-3 cells. Also, we established luteolin-mediated inhibition of the PI3K/AKT pathway and activation of the ERK1/2 pathway as being responsible for the antiproliferative activity of luteolin. In addition, we compared viability of choriocarcinoma cells in response to luteolin and three conventional chemotherapeutic agents alone and in combination. Finally, our results provide strong evidence that SREBP1 is a target gene of luteolin that is also involved in lipogenic gene-mediated cancer progression (Fig. 11) .
Choriocarcinoma is commonly managed using a multidrugbased chemotherapy with drug regimens like EMA-CO and etoposide, methotrexate, actinomycin D, etoposide, and cisplatin (EMA-EP) [18] . However, a few patients are resistant to those therapies and there are unable to avoid surgical interventions. Additionally, administration of the drugs at high concentrations can have a direct adverse effect on a viable fetus [19] . Recently, there has been development of drugs that are more effective and have fewer side effects in patients treated for choriocarcinomas. Several regimens that include paclitaxel and cisplatin can act as effective salvage treatments for relapsed patients for whom therapy with first-line EMA-CO regimen has failed [20] .
These days, natural products derived from plants have been highlighted in cancer therapy. Many types of flavones including luteolin, apigenin, and chrysin are widely known for antiproliferative and antimigratory activity in various types FIG. 9 . Differential expression of SREBP-mediated target genes in the choriocarcinoma cell lines in response to luteolin. The expression of mRNAs for SREBP regulatory target genes was estimated for control and luteolin-treated JAR (A) and JEG-3 (B) cells. Quantitative RT-PCR analyses were performed using cDNA templates from luteolin-treated and -untreated choriocarcinoma cells (mean 6 SEM; P , 0.001). These experiments were performed in triplicate and normalized to control GAPDH expression. *Significant differences compared to untreated controls (***P , 0.001; **P , 0.01; *P , 0.05).
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of cancers [21] . Among them, luteolin is the most common compound contained in a number of dietary sources. However, the effects of phytochemicals on choriocarcinoma cells have been rarely studied. In the present study, we determined that luteolin effectively and dose-dependently decreases viability of choriocarcinoma JAR and JEG-3 cells, but does not affect normal trophoblast HTR8/SVneo cells. PCNA was detected in low abundance in luteolin-treated choriocarcinoma cells whereas there was abundant PCNA in nuclei of untreated choriocarcinoma cells. Furthermore, luteolin-mediated increases in apoptotic cells was confirmed through TUNEL reaction and annexin V staining. These results indicate that proliferation and viability of JAR and JEG-3 cells are highly influenced by luteolin and that luteolin mediates important anticancer effects via specific cell signaling cascades.
Luteolin-mediated inhibition of PI3K/AKT is well known for some cancer types. For example, luteolin's antimetastatic effects on colon cancer cells and on gastric cancer cells involve inhibition of phosphorylation of AKT [4, 22] . However, effects of luteolin on human choriocarcinoma cells are not known. Overexpression of AKT is involved in proliferation of choriocarcinoma cells [23] . Results of the present study revealed dose-or time-dependent effects of luteolin to inhibit phosphorylation of AKT in JAR and JEG-3 cells, as well as a downstream molecule of AKT, P70S6K. Phosphorylation of P70S6K via the PI3K/AKT/mTOR pathway is important for proliferation, survival, and chemotherapy resistance in cancer cells [24] . Based on these results, luteolin-mediated inhibition of phosphorylation of P70S6K would account, in part at least, for decreasing the viability of JAR and JEG-3 cells. GSK3b is another downstream target of AKT which inactivates glycogen synthase [25] . However, apoptotic effects of GSK3b are controversial because it plays a role in both proapoptotic and antiapoptotic signaling pathways, dependent on cellular environments [26] . As shown in Figure 3C , phosphorylation of GSK3b on Ser9 differed between JAR and JEG-3 cells, suggesting that the signaling pathway mediated by luteolin differs between the two choriocarcinoma cell lines. In addition, p-ERK1/2 increased in response to luteolin treatment in a dosedependent manner in both of the choriocarcinoma cell lines, but activation of P90RSK, which is downstream of ERK1/2, was also differently affected by luteolin between JAR and JEG-3 cells. Published results indicated activation of GSK3b by ERK1/2 or P90RSK [27] . Results of the present study indicate that luteolin induces PI3K/AKT and ERK1/2 cell signaling that influences cross-activation and cross-inactivation of signaling pathways in JAR and JEG-3 cells [27] . Differential signal transduction effects of luteolin on JAR and JEG-3 cells reflects the different characteristics those cell lines. For example, JAR cells derive from a primary placental-site tumor, whereas JEG-3 cells are a clonal cell line derived from brain tumor. In addition, JAR cells are estrogen receptor alpha (ER-a)-positive and p53 wild type, whereas JEG-3 cells are ER-a-negative and have a p53 mutation [28, 29] . Also, JAR cells are a pseudotriploid cell line and JEG-3 cells also have a high chromosome count. Therefore, the different cell signaling cascades between the two choriocarcinoma cells are now known, but further experiments, beyond the scope of the present study, are necessary for identify mechanisms underlying the differences. Additionally, some studies of the proapoptotic role of ERK1/2 support our evidence for ERK1/2 cell signaling mediating apoptotic functions of luteolin in choriocarcinoma cells.
Luteolin suppressed activity or expression of some membrane receptors involved in cell proliferation or apoptosis. For example, fms-like tyrosine kinase 3 (FLT3), a member of receptor tyrosine kinases, is inactivated at high concentrations of luteolin in acute myeloid leukemia cells [30] , and it regulates AKT/P70S6K proteins in skin cancer targeted by coumestrol [31] . In addition, luteolin has inhibitory effects on expression of EGFR and reduces EGF-induced phosphorylation of AKT in breast cancer [32] . In human choriocarcinoma cells, the EGFRmediated PI3K/AKT pathway promotes cancer cell progression [33] . Collectively, we suggest that inhibitory effects of luteolin on the PI3K/AKT pathway are essential for luteolin-mediated suppression of choriocarcinoma cell growth. Results of the proliferation assays indicated inhibition of PI3K/AKT that reinforced luteolin-induced cell death in JAR, but not JEG-3 cells. Instead, only ERK1/2 inactivation significantly decreased viability in JEG-3 cells as compared to luteolin or U0126 alone. In spite of similarities between JAR and JEG-3 cells in secretion of chorionic gonadotropin and steroids, they differ in proliferation and differentiation characteristics. Proliferation of JAR cells is greater than for JEG-3, but JAR cells are less well differentiated than JEG-3 cells [28] . However, these differences in JAR and JEG-3 cells in response to each signal transduction inhibitor require further study. Expression of AKT pretreatment of choriocarcinoma cells with three inhibitors including LY294002, U0126, and rapamycin clarified cell signaling pathways activated by luteolin. U0126 and rapamycin did not negatively regulate p-AKT expression compared to luteolin alone. Meanwhile, p-ERK1/2 expression was upregulated by inhibition of AKT. These results revealed that ERK1/2 MAPK pathway is highly influenced by PI3K/ AKT signal transduction cascade. Moreover, phosphorylated GSK3b was strongly reduced by inhibition of PI3K/AKT in JEG-3 but not JAR cells. Consistent with previous results, GSK3b is suggested to be directly regulated by AKT, especially in JEG-3 cells. These results may be closely associated with p53 status of each cell line. The p53 mutant enhances chemoresistance, mitogenic defects and genomic instability by increasing invasion, migration, scattering, angiogenesis, and proliferation in various cancer cells [34, 35] . Thus, viability of JAR (p53 wild type) and JEG-3 (mutant p53) cells differ in response to conventional chemotherapeutic agents. Also, the divergent characteristics between JAR and JEG-3 cells likely originated from p53 mutations that can result in responses to chemotherapeutics via multiple signal transduction pathways. The constitutive phosphorylation of GSK3b involves the C-terminal basic domain and N-terminal amino acids of p53 and regulates actions that determine cell fate [36, 37] . Suppression of GSK3b activity increases correlations with transcriptional and apoptotic actions mediated via p53 cell signaling. In the present study, there was differential phosphorylation of GSK3b protein in response to luteolin according to p53 status of JAR (wild-type) and JEG-3 (p53 mutant) cells.
Significant inactivation of AKT and P70S6K suggests that phosphorylated mTOR, another target molecule of AKT, would be decreased by luteolin in JAR and JEG-3 cells. As shown in Figure 7B , phosphorylation of mTOR was decreased by luteolin in a dose-dependent manner in JAR and JEG-3 cells. It is known that mTOR plays an essential role in de novo lipid synthesis, including fatty acid and cholesterol synthesis [38, 39] . One of the downstream molecules of the PI3K/AKT/ FIG. 11. Schematic illustrates the current working hypothesis regarding anticancer mechanisms of luteolin targeting multiple signaling pathways in choriocarcinoma cells. Luteolin affects transmembrane receptors such as receptor tyrosine kinase (RTK) and G protein-coupled receptor (GPCR)-initiating intracellular signaling pathways. Suppression of RTK activity by luteolin inhibits PI3K/AKT cell signaling leading to decreases in its downstream signaling proteins including mTOR, P70S6K, and S6, which regulate protein synthesis related to decreasing proliferation and viability of choriocarcinoma cells. Also, as mTOR is down-regulated by luteolin, there is a decrease in phosphorylated SREBP that reduces transcription of lipogenic genes regulating cholesterol and fatty acid synthesis. However, luteolin activates GPCR-inducing Ras-MEK1/2-ERK1/2 signal transduction in choriocarcinoma cells, and this has antitumor effects. mTOR pathway is SREBP which acts as an intracellular sterol sensor. If intracellular sterol is abundant, SREBP strongly binds SCAP in the endoplasmic reticulum. Under conditions of sterol depletion, SREBP is released from the endoplasmic reticulum and transported to the Golgi apparatus. Then, SREBP is cleaved two times, and the N-terminal fragments moved to the nucleus. In the nucleus, SREBP binds to sterol regulatory elements (SREs) and induces transcription of target genes encoding lipogenic enzymes including ACACA, FASN and SCD [40] . In cancer cells, lipid metabolism is altered abnormally, so several genes related to lipid synthesis are recognized as novel targets of cancer therapy at the transcriptional or posttranslational levels [41] . There are three isoforms of SREBP (SREBP1a, SREBP1c, and SREBP2) which have different roles in lipid synthesis. SREBP1 mediates fatty acid metabolism, and SREBP2 is primarily involved in cholesterol metabolism. We first confirmed that luteolin negatively regulates SREBP1, SREBP2, and SCAP mRNA expression in JAR and JEG-3 cells. However, SREBP1 protein, but not SREBP2 protein, was significantly decreased by luteolin in a dose-dependent manner in JAR and JEG-3 cells. In addition, SREBP1 was abundant in the nuclei of both JAR and JEG-3 control cells, but the abundance of SREBP1 was significantly decreased and localized to the cytoplasm in JAR cells, while SREBP1 was barely detectable in luteolin-treated JEG-3 cells. In contrast, SREBP2 abundance and cellular localization was not affected by luteolin in either choriocarcinoma cell line. Next, we analyzed expression of mRNAs of 10 genes targeted by functional SREBP. FASN is an enzyme that synthesizes palmitate from acetyl-CoA and malonyl-CoA, and is up-regulated in various types of cancers including trophoblastic neoplasm [42] . ACACA carboxylases convert acetylCoA to malonyl-CoA, and is a target enzyme to down-regulate proliferation and invasion of breast cancer cells [43] . PPARc is involved in lipid uptake and adipogenesis, and is increased by functional SREBP1 during differentiation of adipose tissue [44] . DBI, also known as an acyl-CoA binding protein, is an intracellular carrier of acyl-CoA esters, and its transcriptional activation is regulated by SREBP1a [45] . SCD catalyzes a ratelimiting step in the synthesis of unsaturated fatty acids, and is a main target gene of SREBP1 in pancreatic cancer therapy [46] . The other enzymes including HMGCR, HMGCS1, FDFT1, MVK, and SQLE are all involved in cholesterol synthesis, and they also promote progression of human cancers [47, 48] . Expression of most of these genes was significantly reduced in the luteolin-treated choriocarcinoma cell lines. These results suggest that antiproliferative effects of luteolin may involve changes of these target genes involved in lipid metabolism.
Results of the present study clearly indicate that luteolin has anticancer effects in two choriocarcinoma cell lines. Treatment of those cells with luteolin decreased proliferation, viability, and mitochondrial membrane potential and inhibited PI3K/ AKT cell signaling as well as the mTOR/SREBP axis to alter lipid metabolism. Therefore, luteolin can act as a novel therapeutic agent for patients resistant to conventional chemotherapy for choriocarcinomas.
